Josephine van Dongen

3 Updated cost-effectiveness and risk-benefit analysis 77 50. Friesema IH, Lugner AK, van DuynhovenYT, Group GEW. Costs of gastroenteritis in the Netherlands, with special attention for severe cases. Eur J Clin Microbiol Infect Dis. 2012;31(8):1895–900. 51. van den Brandhof WE, DeWit GA, deWit MA, van DuynhovenYT. Costs of gastroenteritis in the Netherlands. Epidemiol Infect . 2004;132(2):211–21. 52. Haagsma JA, Geenen PL, Ethelberg S, Fetsch A, Hansdotter F, Jansen A, Korsgaard H, O’Brien SJ, Scavia G, Spitznagel H, et al. Community incidence of pathogen-specific gastroenteritis: reconstructing the surveillance pyramid for seven pathogens in seven European Union member states. Epidemiol Infect . 2013;141(8):1625–39. 53. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF therapy: results from the COIN study. Gut . 2014;63(1):72–9. 54. (Statistiek) SNCBvd: Beroepsbevolking; kerncijfers naar geslacht en andere ken- merken 1996–2014. 13 Februar 2015 edn; 2015. 55. Vesikari T, Dennehy P, Matson D, Itzler R, Dallas M, Goveia M, DiNubile M, Heaton P, Lawrence J, Ciarlet M. Efficacy of Rotateq®, the pentavalent rotavirus vaccine, between doses: potential benefits of early protection [abstract]. Arch Dis Child . 2008;93:pw 70. 56. Vesikari T, Itzler R, Karvonen A, Korhonen T,Van DP, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine. 2009;28(3):345–51. 57. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr. 2010;169(11):1379–86.